Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended March 31, 2012—Palatin’s fiscal 2012 third quarter, notwithstanding the request metadata’s “2011 Q3.” Financial statements are unaudited.
Business context and operating focus
Palatin is a development-stage biopharmaceutical company. Its lead candidate, bremelanotide for female sexual dysfunction (FSD), was in a Phase 2B trial. AstraZeneca was advancing AZD2820 for obesity, which had completed one Phase 1 trial and entered a second. Palatin had stopped early-stage discovery work, was realigning its workforce, and was decommissioning its research laboratory.
Key financial metrics
| Metric | Three months ended March 31, 2012 | Nine months ended March 31, 2012 |
|---|---|---|
| Revenue | $24,000 | $62,705 |
| Operating expenses | $6.05 million | $13.16 million |
| Operating loss | $6.03 million | $13.09 million |
| Net loss | $6.02 million | $12.00 million |
| Basic and diluted loss per share | $0.17 | $0.34 |
Revenue consisted of AstraZeneca contract revenue; the company reported no grant revenue in fiscal 2012. Gross profit and gross margin are not separately reported, and revenue was minimal relative to operating expenses.
- Cash flow: Operating activities used $10.06 million in the nine months, versus $7.89 million in the comparable 2011 period. Investing activities used $10,300 and financing activities used $29,615. Cash and cash equivalents declined $10.10 million to $8.77 million.
- Liquidity and liabilities: At March 31, 2012, current assets were $9.46 million, including $8.77 million cash and $16,600 receivables; current liabilities were $3.44 million. Total liabilities were $3.54 million. The filing reports capital lease obligations totaling approximately $47,500 and no other borrowings.
- Capital and equity: Stockholders’ equity was $6.91 million, down from $18.19 million at June 30, 2011. Accumulated deficit was $233.99 million. Common shares outstanding were 34,900,591 as of March 31 and May 11, 2012.
Changes versus the prior comparable period
- Quarterly revenue fell to $24,000 from $61,294; nine-month revenue fell to $62,705 from $1.32 million, primarily because the prior-year period included $846,768 of grant revenue and higher AstraZeneca contract revenue.
- Quarterly R&D expense rose to $4.71 million from $1.72 million; nine-month R&D expense rose to $9.68 million from $7.16 million. Management attributed the increase primarily to the ongoing bremelanotide Phase 2B trial, which began in June 2011.
- Quarterly net loss widened to $6.02 million from $3.81 million. Nine-month net loss increased to $12.00 million from $9.51 million. Prior-year losses included a $1.26 million charge related to the increase in fair value of warrants.
- Nine-month cash used in operations increased by approximately $2.17 million. The prior-year period included $21.1 million in financing proceeds, primarily from a public offering; there were no comparable financing proceeds in fiscal 2012.
Outlook, risks, and unusual items
- Management believed available cash and receivables would fund currently planned operations, focused on the bremelanotide Phase 2B trial, through March 31, 2013. Palatin expected a significant loss for the fiscal year ending June 30, 2012 and additional losses for at least the next few years.
- Management anticipated completing Phase 2B patient studies in the third calendar quarter of 2012 and announcing top-line results shortly thereafter. Phase 3 trials, not expected to begin before calendar 2013, would require significant additional capital. Funding was not assured; absent financing, the company could need to seek collaborators earlier or dispose of product rights on less favorable terms.
- Palatin reported that it would not substantially fund PL-3994 or other programs without additional capital or collaborations. Revenue concentration was significant: 100% of license and contract revenue in the reported periods came from AstraZeneca.
- The company recognized a $1.07 million tax benefit in the nine-month period from selling New Jersey net operating loss carryforwards. It issued Chardan Capital Markets warrants to purchase up to 150,000 shares as partial payment for advisory services.
- A newly highlighted risk concerns laboratory decommissioning and hazardous-material disposal. Contamination or injury could result in liabilities that exceed the company’s financial resources or insurance. The company reported no current legal proceedings and no material changes to other previously disclosed risk factors.
Important facts for investors to verify
- Whether the Phase 2B trial completed on the anticipated schedule and what its results showed.
- Current cash runway, subsequent financing, and the funding plan for Phase 3 and other development programs.
- Clinical and regulatory progress for bremelanotide and AstraZeneca’s AZD2820, including any collaboration milestones or payments.
- Costs, timing, and potential liabilities associated with laboratory closure and hazardous-material disposal.
- The filing’s fiscal-period identification: the reported quarter ended March 31, 2012, not 2011.